New hope for pancreatic cancer: experimental drug combo enters human trials
NCT ID NCT07114861
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether adding two experimental drugs (KN510 and KN713) to standard chemotherapy (mFOLFIRINOX) is safe and effective for people with advanced pancreatic cancer that cannot be removed by surgery. About 30 adults aged 19–75 who have not had prior chemo for advanced disease will take part. The study will first find the best dose, then expand to see how well the combination controls tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KN510713 (two experimental drugs) plus mFOLFIRINOX chemotherapy
- What this could lead to
- If successful, this combination could offer a new treatment option for advanced pancreatic cancer, potentially shrinking tumors or slowing disease progression.
- What could go wrong
- This is an early-phase trial with only 30 participants, so results may not apply broadly. The experimental drugs could cause side effects or fail to improve outcomes over standard chemo alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center
RECRUITINGGoyang-si, South Korea